What Is CJC-1295 Hormone Release?
What is CJC-1295/Ipamorelin?
AAI is excited to introduce the newest in Peptide Therapy. The combination of Ipamorelin and CJC-1295 is similar to that of our Sermorelin with the GHRP’s 6/2 with fewer side effects. Using a GH along with a GHRP has a synergistic impact on stimulating GH and IGF-1 levels will increase the clinical outcomes for our patients.
CJC-1295 has shown some fantastic results as a growth hormone releasing peptide (GHRP) analog. Not only has CJC-1295 demonstrated the potential to increase growth hormone and IGF-I secretion. CJC-1295 Stimulates (GHS) Growth Hormone Secretion, and will keep a steady increase of Growth Hormone and IGF-1, without no increase in prolactin leading to fat loss, and increased protein synthesis thereby promoting growth and more.
CJC-1295 Therapy is a tetra-substituted, 30 amino acid, the primarily functioning in a growth hormone releasing peptide (GHRP) analog, One of the advantages of CJC-1295 over traditional GHRP or HGH is its ability to bio-conjugate with serum albumin, This increasing its half-life and therapeutic window, This accomplishes using protecting groups around the amino acids of GHRP typically susceptible to enzymatic degradation.
There is more benefit with CJC-1295 and its ability to promote slow wave and, (SWS) Slow Wave Sleep also known as the knockout or the Deep Sleep, this will help the body to produce more hormones while your sleep and is the portion of rest responsible for the level of muscle growth and memory retention. Also, Clinical studies have shown that a once-daily administration of CJC-1295 normalizes the response and can induce significantly deeper sleep.
Ipamorelin is a pentapeptide meaning its comprised of amino acids and acts as a GHRP (Growth Hormone Releasing Peptide) In contrast to our typical GHRP’s used with Sermorelin, Ipamorelin does not significantly boost, cortisol, aldosterone, or acetylcholine levels. Patients on different GH secretagogue-based therapies have reported side effects such as jitters, cold sweats, or nervousness, which could be due to the impact of their treatment on cortisol levels. Because Ipamorelin does not have these effects, patients can benefit from just the positive aspects of HGH therapy, while keeping unwanted side effects at bay.
Ipamorelin is one of several secretagogue met-enkephalin analogs that include unnatural D-amino acids. They were developed for their growth hormone releasing (GHR) activity, then called GH secretagogues. They lack opioid activity but are potent stimulators of GH release. These secretagogues are distinct from the growth hormone-releasing (GHR) or Growth Hormone Releasing Peptide (GHRP) in that they share no sequence relation and derive their function through action at a completely different receptor, the ghrelin receptor.
Reported Benefits CJC/Ipamorelin:
INCREASED SKIN ELASTICITY
IMPROVED COGNITIVE FUNCTION/MEMORY
IMPROVED BONE DENSITY
INCREASED MUSCLE MASS AND STRENGTH
DECREASE FAT TISSUE
HEIGHTENED SEXUAL FUNCTION
IMPROVED CARDIOVASCULAR HEALTH
IMPROVED LIPID PROFILE
PROMOTES SLOW WAVE SLEEP